Navigation Links
Spherix Announces the Closing of Private Placement of $2,235,000
Date:11/7/2013

TYSONS CORNER, Va., Nov 7, 2013 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that the Company has closed the previously announced private placement with five accredited investors for gross proceeds to the Company of $2,235,000.  The average price per share in this transaction was $6.34.

(Logo: http://photos.prnewswire.com/prnh/20131104/PH08853LOGO)

CEO Anthony Hayes stated, "The aforementioned closing of the private placement allows Spherix to be opportunistic when patent portfolios that our team identifies as complementary to our existing IP become available.  Our team of professionals continues to identify infringements of our intellectual property of patents that touch in such high use areas as WiFi, Cellular Communication and Antenna technology."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Spherix or shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The shares offered in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (SEC) or through an applicable exemption from SEC registration requirements. The shares of common stock were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the common stock purchased by the investors. Any offering of the Company's securities under the resale registration statement will be made only by means of a prospectus.

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company.  Spherix presently offers a diversified commercialization platform for protected technologies. The company continues to work on life sciences and drug development and presently is exploring opportunities in nutritional supplement products relying on its D-Tagatose natural sweetener as a GRAS ingredient.  Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Forward Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations
Phone: (703) 992-9325
Email: info@spherix.com


'/>"/>
SOURCE Spherix Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
2. Spherix Announces Private Placement as the Company Continues to Execute its Patent Monetization Program - Spherix accepts $2.0 Million from Investors
3. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
4. Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time
5. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
6. Spherix Announces Registered Direct Offering of $1.15 Million
7. Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
8. Spherix Announces Third Quarter Financial Results
9. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
10. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
11. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance for ... a significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI ... Coil Actuator with a flexure design that ensures high alignment accuracy by preventing ... and is ideally suited where extreme precision is required, such as in medical ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):